News and Trends 8 Sep 2022 Report looks at the future of clinical trials Medidata, a Dassault Systèmes company, has published a report, ‘European Industry Research Report: The Future of Clinical Trials’. The report draws on new independent research that includes insights from 400 clinical trial executives across the U.K., France, Germany and Switzerland. They were surveyed to gain a deeper understanding of how clinical trials have changed over […] September 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Omnio receives funding for wound treatment Swedish company Omnio AB has shown plasminogen is a pro-inflammatory regulator of inflammation that can be used to treat chronic wounds with dysfunctional inflammation. The company, a spin off from Umeå University, said the drug could mean a global treatment revolution for wounds that never heal. Non-healing chronic wounds are a major global health problem […] September 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 OncoBone signs deals with three partners to work on bone metastases OncoBone Ventures has signed cooperation framework agreements with three partners. The company is a U.K. start up biotech looking to develop novel therapies for cancer patients with currently incurable bone metastases. The partners are: Okayama University in Japan, the University of Bradford in the U.K., and The Development Center for Biotechnology in Taiwan. The agreements […] September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Arcutis BioTherapeutics will acquire the outstanding shares of Ducentis for an upfront cash payment of approximately $16 million and Arcutis stock valued at approximately $14 million, […] September 8, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Cultivated Biosciences raises $1.5M to take fats to the next frontier Cultivated Biosciences, an ingredient startup biotech company founded by Swiss entrepreneurs Tomas Turner and Dimitri Zogg, has just raised a $1.5M pre-seed round. The funding will enable the growing team to further optimize its production processes, research food applications and start product development of its creamy ingredient for dairy alternatives from non-GMO yeast with their […] September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 7 Sep 2022 Powerful, organic turmeric produced by controlled fermentation process A controlled fermentation process has been used to produce an organic turmeric – a natural herb known for its health benefits and organoleptic properties. German pharmaceutical company, Cellavent, has recently entered the fermented botanical space with product, fermentlife Turmeric. Cellavent says its product is a powerful new organic turmeric that can offer a wide range […] September 7, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Oncopeptides receives grant for NK-cell engager project in multiple myeloma Oncopeptides AB has received a SEK 5 million ($465,000) research grant from Sweden’s Innovation Agency. The Swedish biotech company, which focuses on R&D of therapies for difficult-to-treat hematological diseases, will use the funds to develop a preclinical proof of concept (PoC) for a novel synthetic small polypeptide for the treatment of multiple myeloma. The compound […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 7 Sep 2022 The biggest private biotech investments in August 2022 The healthcare-focused companies Orna Therapeutics, F2G and Sironax bagged the biggest biotech investments in August 2022, with mRNA vaccines, genomics and fermentation technology attracting big funding rounds. As many took a well-deserved vacation in the month of August 2022, the world of biotech remained busy with fundraising. Sit back and browse our lists of the […] September 7, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Lesaffre acquires genome editing company Recombia Biosciences Lesaffre has acquired Recombia Biosciences, a biotech company based in the San Francisco Bay Area founded in 2019 based on technology licensed from Stanford University. This acquisition is the culmination of a strategic partnership initiated in 2020 to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Adocia takes steps with implants for treatment of type 1 diabetes French biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant by achieving glycemic control without insulin injections in immunocompetent diabetic rats during a 132-day study. AdoShell Islets is an immuno-protective synthetic biomaterial containing islets of Langerhans. After implantation in diabetic animals, the islets encapsulated in AdoShell secrete insulin in […] September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 OncoResponse and Regeneron to evaluate drug combo for patients with advanced cancer OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, has announced a clinical supply agreement with Regeneron for PD-1 inhibitor Libtayo (cemiplimab). The supply agreement with Regeneron will support the evaluation of Libtayo in combination with OR2805, a fully human monoclonal antibody identified from an elite cancer responder […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Benchling launches solution to boost mRNA and RNA therapeutics development Benchling has launched what it says is the industry’s first full set of capabilities for designing, modeling, and studying natural and chemically modified RNA in a single solution. As the biopharma industry increases its focus on developing RNA therapeutics, Benchling said its new RNA solution is the first purpose-built offering on the market to help […] September 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email